SynCore Biotechnology Co.,Ltd (4192.TWO)

45.00 +0.30 (+0.67%) At close: 01:23PM CST

SynCore Biotechnology Co.,Ltd

84 Chung Shan Road
Chung Shan Village Tung-Shan, I-Lan
Yilan City 269
Taiwan
886 3 958 6101
https://www.syncorebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 40

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Chih-Wen Lee	Founder & Chairman of the Board	1.05M	N/A	N/A
Dr. Muh-Hwan Su	President & GM	3.85M	N/A	N/A
Mr. Wen-Hsin Huang	VP & Head of Drug Development Department	1.49M	N/A	N/A
Mr. Chia-Hao Liang	Head of Financial & General Affairs Department and Accounting Manager	N/A	N/A	N/A
Mr. Ruey-Wen Lin	Head of Quality Assurance Department	N/A	N/A	N/A

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and SB04,an conventional drug for the treatment of age-related macular degeneration that is in Phase II clinical trials. In addition, the company provides SB05-EndoTAG, an conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. Further, it distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. The company has partnerships with Medigene AG and MacuCLEAR Inc.; Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes. SynCore Biotechnology Co.,Ltd was incorporated in 2008 and is headquartered in Yilan City, Taiwan. The company is a subsidiary of Sinphar Pharmaceutical Co., Ltd.

Corporate governance

SynCore Biotechnology Co.,Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.